SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Procept (PRCT): 50% rise on high volume. Why? -- Ignore unavailable to you. Want to Upgrade?


To: Douglas who wrote (420)7/8/1999 8:23:00 AM
From: Douglas  Read Replies (2) | Respond to of 455
 
Good News: Phase I trials for BG are nearing completion with several Phase II trials scheduled to start in the fall at NCI. Trial Investigators should be releasing their Phase I results this summer. Results must have been good or the NCI wouldn't pursue a Phase II. Procept has determined the maximum tolerated dose for BG. The involvement of the NCI and their funding is a positive sign!